Cohance Lifesciences Limited — Credit Ratings, 29-11-2024: Credit Rating

Suven Pharmaceuticals reported consolidated revenue of ₹1,051 crores for the fiscal year 2024, down from ₹1,341 crores in the previous year, indicating a decline of about 21.6%. Despite this, the first half of the current fiscal year showed a promising topline of ₹488 crores. The company has cited demand fluctuations and operational improvements as potential drivers for stabilization in revenues going forward.

The net profit for fiscal 2024 was ₹300 crores, compared to ₹411 crores the prior year, reflecting a profit margin of 28.56% versus 30.66% in fiscal 2023. The reduction in profitability is attributed to increased operational costs and changes in market dynamics. The Earnings Per Share (EPS) for the year stood at approximately ₹10.

Operational costs have shown minor fluctuations, while the interest coverage ratio remains robust at over 62 times, indicating strong cash generation relative to interest expenses. The balance sheet indicates a solid financial position with a net worth estimated at ₹2,200 crores, while adjusted debt levels remain low at 0.02 times.

The company’s strategic focus appears to be on optimizing operational efficiency and leveraging the successful amalgamation with Cohance Lifesciences to enhance growth potential. The market sentiment is cautiously optimistic, supported by the company's established position within the biopharmaceuticals space.

Given the current financials, Suven Pharmaceuticals is viewed as a potential hold, due in part to the strong liquidity position and anticipated synergies from upcoming corporate actions, though investors should monitor revenue stability closely.